MAP2K7 and metastatic melanoma: Our previous studies also found that primary tumor characteristics maintained their prognostic power as independent variables for survival in metastatic melanoma patients treated with immune checkpoint inhibitors or BRAF and MEK inhibitor combinations [39,40].